View Older Stories View More Recent Stories

Oct 2, 2023 01:17PM Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
Sep 28, 2023 12:02PM Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
Sep 27, 2023 07:00AM Ionis Pharmaceuticals (IONS) enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
Sep 27, 2023 07:00AM Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
Sep 26, 2023 07:01AM Ionis Pharmaceuticals (IONS) Phase 3 study of olezarsen in people with familial chylomicronemia syndrome met its primary endpoint
Sep 26, 2023 07:00AM Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
Sep 12, 2023 07:05AM Ionis to host investor and analyst day event
Aug 30, 2023 07:05AM Ionis to present at upcoming investor conferences
Aug 9, 2023 07:00AM Ionis reports second quarter 2023 financial results
Aug 3, 2023 07:05AM Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
Jul 31, 2023 07:05AM Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
Jul 28, 2023 07:05AM Ionis Pharmaceuticals (IONS) Expands eplontersen Deal with AstraZeneca (AZN) to Include Latin America
Jul 28, 2023 07:05AM Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
Jul 26, 2023 07:05AM Ionis to hold second quarter 2023 financial results webcast
Jul 10, 2023 07:05AM Ionis Pharmaceuticals (IONS) Reports Eplontersen Continued to Show Improvement in ATTRv-PN through 85 weeks
Jul 10, 2023 07:05AM Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
Jul 5, 2023 07:05AM Ionis to present at upcoming investor conference
Jun 30, 2023 04:09PM Biogen (BIIB) Presents New Data on SPINRAZA
Jun 30, 2023 04:08PM New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
Jun 30, 2023 04:06PM New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Jun 1, 2023 07:10AM Ionis Pharmaceuticals (IONS) announces positive donidalorsen late-stage clinical progress in HAE
Jun 1, 2023 07:05AM Ionis announces positive donidalorsen late-stage clinical progress in HAE
May 10, 2023 07:05AM Ionis to host 2023 virtual Annual Meeting of Stockholders
May 9, 2023 07:05AM Ionis to present at upcoming investor conferences
Apr 26, 2023 05:41AM Ionis Pharmaceuticals (IONS) Announces FDA Approval of QALSODY
Apr 25, 2023 07:10PM FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
Apr 24, 2023 07:01AM Ionis Pharmaceuticals (IONS) says Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
Apr 24, 2023 07:00AM Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
Apr 20, 2023 07:05AM Ionis to hold first quarter 2023 financial results webcast
Mar 29, 2023 08:45AM New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
Mar 28, 2023 07:05AM Ionis to present at upcoming investor conferences
Mar 27, 2023 05:49AM Ionis Pharmaceuticals (IONS) Reports Positive 66-week Phase 3 Data for eplontersen
Mar 27, 2023 02:00AM Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
Mar 23, 2023 05:31AM Ionis Pharmaceuticals (IONS) Reports FDA's AdCom Voted Unanimously for Accelerated Approval of tofersen
Mar 22, 2023 11:01PM Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS
Mar 7, 2023 07:06AM Ionis Pharmaceuticals (IONS) announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy
Mar 7, 2023 07:05AM Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Feb 28, 2023 07:05AM Ionis to present at upcoming investor conferences
Feb 22, 2023 07:01AM Ionis reports fourth quarter and full year 2022 financial results
Feb 21, 2023 07:06AM Ionis Pharmaceuticals (IONS) to Present New donidalorsen Data
Feb 21, 2023 07:05AM Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
Feb 8, 2023 07:05AM Ionis to hold fourth quarter and full year 2022 financial results webcast
Feb 1, 2023 09:06AM Ionis Pharmaceuticals (IONS) Announces GSK Initiates Two Phase 3 Trials for bepirovirsen
Feb 1, 2023 09:05AM Ionis announces GSK has advanced bepirovirsen into Phase 3 development
Jan 31, 2023 07:07AM Ionis Pharmaceuticals (IONS) Granted FDA Fast Track Designation for olezarsen
Jan 31, 2023 07:05AM Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
Jan 26, 2023 09:30AM Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research
Jan 9, 2023 09:15AM Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
Jan 9, 2023 09:15AM Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
Jan 9, 2023 09:06AM Ionis Pharmaceuticals (IONS), Royalty Pharma (RPRX) enter into royalty agreement for up to $1.1 billion
View More Recent Stories View Older Stories